Abstract
Amomum villosum Lour. (A. villosum), a comestible medicinal plant, has been traditionally used in China to treat diarrhea, stomach fullness, and abdominal distension. Polysaccharide, the main chemical component of A. villosum, has been shown to possess potential antioxidant and glycosidase inhibitory activities; however, whether it has anticolitis activity is unknown. The aim of this research was to evaluate the anticolitis effects of A. villosum polysaccharide (AVLP) in BALB/c mice. The results showed that AVLP administration significantly reversed body weight loss, colon shortening and colon weight gain and decreased the levels of proinflammatory cytokines and chemokines in colitis mice (p < 0.05). AVLP administration also maintained intestinal barrier function by the upregulation of ZO-1 protein expression (p < 0.05). In addition, high-throughput sequencing analysis showed that AVLP possessed a great regulatory effect on the growth of Adlercreutzia, Clostridium, Streptococcus, Parabacteroides, Helicobacter, Odoribacter, and Alistipes (p < 0.05, LDA score > 2). The correlation analysis revealed that the protective effects against colitis of AVLP were highly correlated with intestinal bacterium regulation. These results suggest that AVLP intake could serve as a prospective nutritional strategy for inflammatory bowel diseases.
Funder
Key-Area Research and Development Program of Guangdong Province
Self-innovation Research Funding Project of Hanjiang Laboratory
Chaozhou Science and Technology Plan Project
Subject
Plant Science,Health Professions (miscellaneous),Health (social science),Microbiology,Food Science
Reference55 articles.
1. Interleukin 1beta Blockade Reduces Intestinal Inflammation in a Murine Model of Tumor Necrosis Factor-Independent Ulcerative Colitis;Cell Mol. Gastroenterol. Hepatol.,2022
2. Cui, G., and Yuan, A. (2018). A Systematic Review of Epidemiology and Risk Factors Associated with Chinese Inflammatory Bowel Disease. Front. Med., 5.
3. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis;Gastroenterology,2020
4. Pharmacokinetics, Safety, and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn’s Disease: Results from the Phase 2 HUBBLE Study;J. Crohn’s Colitis,2022
5. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021;Gastroenterology,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献